Back to Research

Organization profile

ImmunOS Therapeutics

ImmunOS Therapeutics is a clinical-stage biopharmaceutical organization that develops first-in-class HLA-based immunotherapies for the treatment of cancer and autoimmune diseases. Its primary technology platform utilizes naturally occurring human leukocyte antigens (HLA) to target multiple innate and adaptive immune checkpoints simultaneously to overcome resistance in difficult-to-treat tumors.

Schlieren, SwitzerlandFounded 2014

Overview

1. Executive Summary (Confidence: High)

ImmunOS Therapeutics AG is a high-impact leader in the myeloid checkpoint field, leveraging its unique HLA-based technology to redefine immuno-oncology.[33] The company achieved a major financial milestone in 2023 by closing an oversubscribed $74 million Series B financing round led by premier investors Samsara BioCapital and Lightspeed Venture Partners.[34] ImmunOS has successfully transitioned its lead program, IOS-1002, into Phase 1b clinical trials, reporting significant efficacy results at the ESMO Congress in October 2025.[35] Specifically, IOS-1002 demonstrated a 71% disease control rate in patients with PD-1 resistant cancers when combined with pembrolizumab, signaling a major potential breakthrough for patients with limited therapeutic options.[35] With a strong transatlantic team and a pipeline expanding into inflammatory diseases, ImmunOS is strategically positioned as a frontrunner in the next generation of multifunctional immunotherapies.[34]

This is an extract of the full organization profile. To access the full company profile, .

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.